Cancer development is closely associated with immunosuppressive tumor
microenvironment (TME) that attenuates antitumor immune responses and promotes tumor …

Immunotherapy has made remarkable strides in cancer therapy over the past decade.
However, such emerging therapy still suffers from the low response rates and immune …

Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

The p53 protein is a transcription factor known as the" guardian of the genome" because of
its critical function in preserving genomic integrity. The TP53 gene is mutated in …

Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer …

Hypoxia, a common feature of the tumor microenvironment in various types of cancers,
weakens cytotoxic T cell function and causes recruitment of regulatory T cells, thereby …

Ovarian cancer and triple-negative breast cancer are among the most lethal diseases
affecting women, with few targeted therapies and high rates of metastasis. Cancer cells are …

Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …

Rho GTPases are a family of small G proteins that regulate a wide array of cellular
processes related to their key roles controlling the cytoskeleton. Cancer is a multistep …

Immunotherapy has become a powerful clinical strategy for treating cancer. The number of
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …